Czuczman MS - Search Results

1

Use of rituximab, the new FDA-approved antibody.

Leget GA, Czuczman MS. Leget GA, et al. Among authors: czuczman ms. Curr Opin Oncol. 1998 Nov;10(6):548-51. doi: 10.1097/00001622-199811000-00012. Curr Opin Oncol. 1998. PMID: 9818234 Review.

2

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. McLaughlin P, et al. Among authors: czuczman ms. J Clin Oncol. 1998 Aug;16(8):2825-33. doi: 10.1200/JCO.1998.16.8.2825. J Clin Oncol. 1998. PMID: 9704735 Corrected and republished. Clinical Trial.

3

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Berinstein NL, et al. Ann Oncol. 1998 Sep;9(9):995-1001. doi: 10.1023/A:1008416911099. Ann Oncol. 1998. PMID: 9818074 Free article. Clinical Trial.

4

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Czuczman MS, et al. J Clin Oncol. 1999 Jan;17(1):268-76. doi: 10.1200/JCO.1999.17.1.268. J Clin Oncol. 1999. PMID: 10458242 Clinical Trial.

5

CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.

Czuczman MS. Czuczman MS. Semin Oncol. 1999 Oct;26(5 Suppl 14):88-96. Semin Oncol. 1999. PMID: 10561023 Clinical Trial.

6

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.

Czuczman MS, Grillo-López AJ, McLaughlin P, White CA, Saleh M, Gordon L, LoBuglio AF, Rosenberg J, Alkuzweny B, Maloney D. Czuczman MS, et al. Ann Oncol. 2001 Jan;12(1):109-14. doi: 10.1023/a:1008395214584. Ann Oncol. 2001. PMID: 11249036 Free article. Clinical Trial.

7

A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.

Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. Khorana A, et al. Among authors: czuczman ms. Leuk Lymphoma. 2001 Mar;41(1-2):77-87. doi: 10.3109/10428190109057956. Leuk Lymphoma. 2001. PMID: 11342359 Clinical Trial.

8

Combination chemotherapy and rituximab.

Czuczman MS. Czuczman MS. Anticancer Drugs. 2001 Jun;12 Suppl 2:S15-9. Anticancer Drugs. 2001. PMID: 11508932 Review.

9

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH. Czuczman MS, et al. Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40. Semin Oncol. 2002. PMID: 11842387 Review.

10

Immunochemotherapy in indolent non-Hodgkin's lymphoma.

Czuczman MS. Czuczman MS. Semin Oncol. 2002 Apr;29(2 Suppl 6):11-7. doi: 10.1053/sonc.2002.32748. Semin Oncol. 2002. PMID: 12040529 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

182 results

Search Page